The U.S. Food and Drug Administration (FDA) has requested drugmakers remove suicide risk warnings from widely used GLP-1 weight-loss drugs like Wegovy and Zepbound. This decision follows a comprehensive review of clinical trials involving over 100,000 patients, which found no evidence linking these medications to an increased risk of suicidal thoughts or other psychiatric side effects. The FDA had previously acknowledged a potential small risk due to limited data but further analysis confirmed no such link.